NASDAQ:PULM

Pulmatrix Q3 2026 Earnings Results & Report

Pulmatrix logo
$1.42 +0.08 (+5.97%)
Closing price 04:00 PM Eastern
Extended Trading
$1.37 -0.05 (-3.80%)
As of 04:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pulmatrix beat analyst earnings expectations in its Q3 2026 results, released November 17, 2026. The company reported EPS of -$0.34 versus the -$2.00 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2026
Time
Before Market Opens
Conference Call Date
Conference Call
7:00 AM ET

Pulmatrix EPS Results

Actual EPS
-$0.34
Consensus EPS
-$2.00
Beat/Miss
Beat by +$1.66
One Year Ago EPS
N/A

Pulmatrix Revenue Results

Actual Revenue
N/A
Expected Revenue
$1.53 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Pulmatrix Q3 2026 Earnings FAQ

Pulmatrix (NASDAQ:PULM) reported earnings of -$0.34 per share for Q3 2026, beating the consensus estimate of -$2.00. The report was announced on Tuesday, November 17, 2026.

Pulmatrix Earnings Headlines

The next convergence is here
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This past May, flooding cut the supply route into the largest uranium complex on the planet, and in July Cigar Lake went down a second time. Gerardo Del Real calls this the Third Convergence Event and has backed three small companies positioned in front of it.tc pixel
See More Pulmatrix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pulmatrix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pulmatrix and other key companies, straight to your email.

About Pulmatrix

Pulmatrix (NASDAQ:PULM) is a clinical-stage biopharmaceutical company developing inhaled therapies. Its proprietary iSPERSE technology is designed to deliver dry-powder medicines to the lungs, and the company’s work has included treatments for respiratory diseases as well as medicines delivered through the lungs for other conditions.

Among its drug candidates, PUR1900 is an inhaled formulation of itraconazole being developed for allergic bronchopulmonary aspergillosis, a lung condition associated with fungal sensitivity. PUR3100 is an inhaled formulation of dihydroergotamine being studied as a potential treatment for acute migraine.

Founded in 2003, Pulmatrix is based in the United States. Its candidates are in clinical development, and the company’s activities focus on research and development rather than marketing approved medicines.

View Pulmatrix Profile